Forward Pharma CFO to Present at the Deutsche Bank Health Care Conference
May 02 2016 - 8:30AM
Forward Pharma A/S (NASDAQ:FWP) (the “Company”), a
biopharmaceutical company working to advance a proprietary
formulation of DMF (dimethyl fumarate) for the treatment of
inflammatory and neurological indications, today announced that
Joel Sendek, the Company’s Chief Financial Officer, will
participate in the following conference:
- Deutsche Bank Annual Health Care Conference to be held at the
InterContinental Hotel in Boston, Massachusetts. Mr. Sendek will
present on Thursday, May 5th at 12:50 PM EST.
Investors and other interested parties may
access a live audio webcast of the conference presentations by
visiting the investor page on the Company’s website
(www.forward-pharma.com). The audio replay will be available
via our website for 90 days following the presentation.
About Forward Pharma:Forward Pharma A/S is a
Danish biopharmaceutical company developing FP187, a proprietary
formulation of DMF (dimethyl fumarate) for the treatment of
inflammatory and neurological indications. Since our founding in
2005, we have worked to advance unique formulations of DMF, which
is an immune modulator, as a therapeutic agent to improve the
health and well-being of patients with immune disorders including
multiple sclerosis. FP187, our clinical candidate, is a DMF
formulation in a delayed and slow release oral dose.
Our principal executive offices are located at Østergade 24A,
1st Floor, 1100 Copenhagen K, Denmark, and our American Depositary
Shares are publicly traded on NASDAQ Stock Market (FWP). For more
information about the Company’s products and developments, please
visit our web site at http://www.forward-pharma.com.
Forward Looking Statements:Certain statements
in this press release may constitute “forward-looking statements”
of the Company within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include,
but are not limited to, statements which contain language such as
“believe,” “expect,” “anticipate,” “hope,” “would” and “potential.”
Forward-looking statements are predictions only which involve known
and unknown risks, uncertainties and other factors that may cause
actual results to be materially different from those expressed in
such statements. Many such risks, uncertainties and other factors
are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the
following: the Company’s ability to obtain, maintain and defend
issued patents with protective claims; the issuance and term of
patents; the Company’s ability to prevail in or obtain a favorable
decision in any patent interference or infringement action; the
Company’s ability to recover damages in any patent infringement
action; uncertainties relating to our development plans and
activities, including the commencement of any clinical trial and
the results, timing, cost and location thereof; risks and
uncertainties related to the scope, validity and enforceability of
our intellectual property rights in general and the impact on us of
patents and other intellectual property rights of third parties;
our ability to commercialize and generate revenue from our sole
clinical candidate, FP187; clinical development, and clinical
trials of FP187 may not be successful; completion of required
clinical trials may take longer than we anticipate, which could
result in increased costs, limit our access to funding and delay or
limit our ability to obtain regulatory approval for FP187. These
and other factors are identified and described in detail in certain
of our filings with the United States Securities and Exchange
Commission, including our Annual Report on Form 20-F for the year
ended December 31, 2015.
Forward Pharma A/S Media Contact:Sharon Klahre,
Director, Investor RelationsForward Pharma USA, LLC7 Skyline
DriveHawthorne, NY 10532SK@forward-pharma.com+1 914-752-3542
The Ruth GroupLee Rothlroth@theruthgroup.com+1 646-536-7014
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Sep 2023 to Sep 2024